Highlights
1 patent
About
Minimally Invasive Solution for Mitral Valve Regurgitation
MitralCord is developing a simple, minimally invasive "place and forget" transcathetertransseptal solution for mitral valve regurgitation, one of the primary types of heart disease worldwide. Based on standard cardiac procedures and materials, MitralCord's solution is performed on a beating heart and eliminates the risks of open surgery, enabling a minimal hospitalization period and short patient recovery time for improved patient wellbeing and quality of life. The solution is well into its R&D phase, already successfully passing the proof-of-concept stage and several preclinical animal studies.
Identity
| Name | MitralCord |
|---|---|
| Slug | mitralcord |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoPGAuPgJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Pardes Hanna-Karkur |
| HQ address | Shkedim St 11, Pardes Hanna-Karkur, Israel |
Web & social
| https://www.linkedin.com/company/18881763 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B2C
Tags
heart-diseasesheart-failurehealthcare-providersminimally-invasivecardiologyhospitalssurgeonsmedical-devices
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}